INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
that the Company has repaid all of its outstanding convertible
notes. The full text of the press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K.
|
Exhibit Number
|
Description
|
|
99.1
|
Press release issued March 22, 2017, reporting that the
Company has repaid all of its outstanding convertible notes. |
About INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV)
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe. INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Recent Trading Information
INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) closed its last trading session down -0.007 at 0.103 with 1,679,927 shares trading hands.